Jaguar Health granted Napo a Type C Meeting by FDA

Jaguar Health (JAGX) announced that the FDA has granted Napo a Type C Meeting in the second quarter to discuss the responder analysis in the prespecified subgroup of patients with breast cancer for crofelemer in Napo’s Phase 3 OnTarget trial. Patients with breast cancer accounted for 183 of the 287 participants in this unprecedented prophylactic clinical trial recently conducted by Napo for diarrhea in adults with solid tumors receiving targeted therapy with or without standard chemotherapy. The American Cancer Society expects 316,950 new cases of breast cancer diagnosed in women in the US in 2025, and it’s estimated that there were 4 million US women with a history of invasive breast cancer in 2022.